BR112018015690A2 - anticorpos tgfbeta 2 - Google Patents

anticorpos tgfbeta 2

Info

Publication number
BR112018015690A2
BR112018015690A2 BR112018015690A BR112018015690A BR112018015690A2 BR 112018015690 A2 BR112018015690 A2 BR 112018015690A2 BR 112018015690 A BR112018015690 A BR 112018015690A BR 112018015690 A BR112018015690 A BR 112018015690A BR 112018015690 A2 BR112018015690 A2 BR 112018015690A2
Authority
BR
Brazil
Prior art keywords
tgf
antibodies
human
tgfbeta
relates
Prior art date
Application number
BR112018015690A
Other languages
English (en)
Inventor
Meyer Angelika
Trendelenburg Anne-Ulrike
Jacobi Carsten
Ibebunjo Chikwendu
Schaadt Eveline
Vladimirovna Mitina Olga
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58191507&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112018015690(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112018015690A2 publication Critical patent/BR112018015690A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

a presente invenção refere-se ao campo de anticorpos anti-transformador de fator de crescimento beta 2 (tgf-ß2). em particular, a presente invenção refere-se a anticorpos monoclonais humanos que ligam a isoforma tgf-ß2 humana preferivelmente sobre as isoformas tgf-ß1 ou tgf-ß3 humanas.
BR112018015690A 2016-02-17 2017-02-17 anticorpos tgfbeta 2 BR112018015690A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662296282P 2016-02-17 2016-02-17
PCT/IB2017/050917 WO2017141208A1 (en) 2016-02-17 2017-02-17 Tgfbeta 2 antibodies

Publications (1)

Publication Number Publication Date
BR112018015690A2 true BR112018015690A2 (pt) 2018-12-26

Family

ID=58191507

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018015690A BR112018015690A2 (pt) 2016-02-17 2017-02-17 anticorpos tgfbeta 2

Country Status (21)

Country Link
US (1) US11180546B2 (pt)
EP (1) EP3416982A1 (pt)
JP (1) JP2019511911A (pt)
KR (1) KR20180107151A (pt)
CN (1) CN108699142A (pt)
AU (1) AU2017219254B2 (pt)
BR (1) BR112018015690A2 (pt)
CA (1) CA3012294A1 (pt)
CL (1) CL2018001941A1 (pt)
CO (1) CO2018008590A2 (pt)
CU (1) CU20180088A7 (pt)
EA (1) EA201891724A1 (pt)
EC (1) ECSP18064646A (pt)
HK (1) HK1257455A1 (pt)
IL (1) IL261065A (pt)
MA (1) MA44236A (pt)
MX (1) MX2018010021A (pt)
PH (1) PH12018501525A1 (pt)
RU (1) RU2018131123A (pt)
SG (1) SG11201805941WA (pt)
WO (1) WO2017141208A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201610044D0 (en) 2016-06-08 2016-07-20 Ucb Biopharma Sprl Antibodies
EP4007774A1 (en) 2019-08-01 2022-06-08 Vaccinex, Inc. Combined inhibition of semaphorin-4d and tgfb and compositions therefor
AU2021236660A1 (en) 2020-03-19 2022-08-18 Genentech, Inc. Isoform-selective anti-TGF-beta antibodies and methods of use
AU2022219373A1 (en) 2021-02-15 2023-08-24 Takeda Pharmaceutical Company Limited Cell therapy compositions and methods for modulating tgf-b signaling
CN112940119B (zh) * 2021-04-26 2022-05-20 北京芳渟阳生生物科技有限公司 一种单克隆抗体及其与间充质干细胞外泌体的联合应用
WO2023201310A1 (en) 2022-04-13 2023-10-19 HCW Biologics, Inc. Multi-chain chimeric polypeptide for use in the treatment of circardian clock gene disorder
WO2023201311A1 (en) 2022-04-13 2023-10-19 HCW Biologics, Inc. Multi-chain chimeric polypeptide for use in the treatment of treating neuroinflammatory disorder

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
GB9206861D0 (en) * 1992-03-28 1992-05-13 Univ Manchester Wound healing and treatment of fibrotic disorders
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
DK1087013T3 (da) 1992-08-21 2009-05-11 Univ Bruxelles Immunoglobuliner uden lette kæder
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US7368111B2 (en) 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
GB9601081D0 (en) * 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP1724282B1 (en) 1997-05-21 2013-05-15 Merck Patent GmbH Method for the production of non-immunogenic proteins
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
IL129299A0 (en) 1999-03-31 2000-02-17 Mor Research Applic Ltd Monoclonal antibodies antigens and diagnosis of malignant diseases
PT1914244E (pt) 1999-04-09 2013-07-26 Kyowa Hakko Kirin Co Ltd Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico
EP1990409A3 (en) 1999-07-20 2011-05-18 MorphoSys AG Bacteriophage
JP2001206899A (ja) 1999-11-18 2001-07-31 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
CA2441903C (en) 2000-05-26 2012-07-31 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
DE60139720D1 (de) 2000-06-28 2009-10-08 Glycofi Inc Verfahren für die Herstellung modifizierter Glykoproteine
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP1443961B1 (en) 2001-10-25 2009-05-06 Genentech, Inc. Glycoprotein compositions
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
EP1874818B1 (en) 2005-04-22 2011-04-13 Eli Lilly And Company Tgf beta 1 specific antibodies
CA2970873C (en) 2005-05-09 2022-05-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
EP1948675B1 (en) 2005-10-25 2014-07-30 The Johns Hopkins University Methods and compositions for the treatment of marfan syndrome and associated disorders
EP3222634A1 (en) 2007-06-18 2017-09-27 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
US20090087443A1 (en) * 2007-09-27 2009-04-02 Bartels Stephen P Pharmacological Adjunctive Treatment Associated with Glaucoma Filtration Surgery
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
KR20110074850A (ko) 2008-08-25 2011-07-04 앰플리뮨, 인크. Ｐｄ-１ 길항제 및 그의 사용 방법
CA2736829C (en) 2008-09-12 2018-02-27 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
AU2009296392B2 (en) 2008-09-26 2016-06-02 Dana-Farber Cancer Institute, Inc. Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
SI2424895T1 (en) 2009-04-27 2018-01-31 Novartis Ag Ingredients and procedures for increasing muscle growth
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
CA2791930A1 (en) 2010-03-11 2011-09-15 Kerry Louise Tyson Pd-1 antibody
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
US8800906B2 (en) 2010-12-27 2014-08-12 The Board Of Trustees Of The Leland Stanford Junior University Use of transforming growth factor-beta neutralizing antibodies and fusion proteins thereof in treating pain
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
KR102051014B1 (ko) * 2011-06-03 2019-12-04 조마 테크놀로지 리미티드 Tgf-베타에 특이적인 항체
AU2012288413B2 (en) 2011-07-24 2016-10-13 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
EP2992017B1 (en) 2013-05-02 2020-11-18 AnaptysBio, Inc. Antibodies directed against programmed death-1 (pd-1)
JP6563906B2 (ja) 2013-05-31 2019-08-21 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｐｄ−１に結合する抗原結合蛋白質
WO2014209804A1 (en) 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
AU2013400609B9 (en) 2013-09-13 2020-03-05 Beigene Switzerland Gmbh Anti-PD1 antibodies and their use as therapeutics and diagnostics
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法

Also Published As

Publication number Publication date
HK1257455A1 (zh) 2019-10-18
KR20180107151A (ko) 2018-10-01
PH12018501525A1 (en) 2019-03-18
EP3416982A1 (en) 2018-12-26
JP2019511911A (ja) 2019-05-09
RU2018131123A3 (pt) 2020-07-09
RU2018131123A (ru) 2020-03-17
WO2017141208A1 (en) 2017-08-24
CU20180088A7 (es) 2019-05-03
CA3012294A1 (en) 2017-08-24
ECSP18064646A (es) 2018-09-30
SG11201805941WA (en) 2018-09-27
US20190092846A1 (en) 2019-03-28
CN108699142A (zh) 2018-10-23
CL2018001941A1 (es) 2018-09-07
MA44236A (fr) 2018-12-26
CO2018008590A2 (es) 2018-08-21
MX2018010021A (es) 2018-11-09
EA201891724A1 (ru) 2019-01-31
US11180546B2 (en) 2021-11-23
AU2017219254A1 (en) 2018-08-02
AU2017219254B2 (en) 2019-12-12
IL261065A (en) 2018-10-31

Similar Documents

Publication Publication Date Title
BR112018015690A2 (pt) anticorpos tgfbeta 2
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
CL2018000829A1 (es) Anticuerpos anti-cd19 humano con alta afinidad
PH12018500714A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
BR112017027778A2 (pt) anticorpos para o fator xi e métodos de uso
WO2017087901A3 (en) Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
BR112018071307A2 (pt) anticorpos agonistas que ligam cd40 humana e usos dos mesmos
EA201792221A1 (ru) Антитела против сортилина и способы их применения
BR112016002199B8 (pt) Anticorpo que se liga a um complexo de hgarp e tgf-b1 latente, composição compreendendo o mesmo, uso e linhagem celular de hibridoma
BR112016024780A2 (pt) composições e métodos relacionados com construtos de fc manipulados
MA40576B1 (fr) Anticorps et immunoconjugués anti-her2
ECSP17045736A (es) Composiciones y métodos para anticuerpos dirigidos a bmp6
BR112015029395A2 (pt) Anticorpos anti-b7-h5 e seus usos
PH12019502025A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
JOP20170004B1 (ar) الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
PH12019501405A1 (en) Anti-neuropilin antigen-binding proteins and methods of use thereof
UY37030A (es) Anticuerpos dirigidos a cd32b y métodos de uso de los mismos
MX2016009877A (es) Anticuerpos anti-baff novedosos.
BR112018075858A2 (pt) anticorpos anti-fator xi de coagulação
CL2015002488A1 (es) Sal de abexinostato novedosa, forma cristalina relacionada, método de preparación de esta y las composiciones farmacéuticas que la contienen
CU20150181A7 (es) Anticuerpos del receptor 1 de ldl oxidado similar a lectina
BR112018002382A2 (pt) novos anticorpos anti-gvpi humano e usos dos mesmos
UY36261A (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso
CU20170012A7 (es) Anticuerpos anti proteína similar a angiopoyetina 4

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2710 DE 13-12-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.